Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
EAST HANOVER, NJ US
1. 20110046397 NEW PROCESSES - new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a 02-24-20112. 20110046193 DEFERACIROX DISPERSIBLE TABLETS - The invention pertains to dispersible tablets comprising as active ingredient 4-[3 5-bis-[1 2 02-24-2011
3. 20110046190 COMBINATIONS COMPRISING A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR 02-24-2011
4. 20110046150 USE OF N--4-(3-PYRIDYL)-2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION 02-24-2011
5. 20110045511 METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD 02-24-2011
6. 20110045062 FORMULATION - This invention relates to a formulation comprising a dipeptidylpeptidase IV inhibitor preferably vildagliptin and metformin 02-24-2011
7. 20110039850 Leukemia Treatment - combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia 02-17-2011
8. 20110039818 Dosage regimen of an S1P receptor agonist 02-17-2011
9. 20110038897 ORAL CONTROLLED RELEASE FORMULATIONS - This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour 02-17-2011
10. 20110037185 CONTINUOUS PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS 02-17-2011
11. 20110034531 USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA 02-10-2011
12. 20110034509 Beta-2-Adrenoreceptor Agonists - Compounds of formula STR00001 in free or salt or solvate form, whereAr is a group of formula STR00002 Y is carbon or 02-10-2011
13. 20110034503 RAPAMYCIN AND ITS DERIVATIVES FOR THE TREATMENT OF LIVER-ASSOCIATED FIBROSING DISORDERS 02-10-2011
14. 20110033533 GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS 02-10-2011
15. 20110033458 COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 02-10-2011
16. 20110033453 USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS 02-10-2011
17. 20110028526 VALSARTAN SOLID ORAL DOSAGE FORMS AND METHODS OF MAKING SUCH FORMULATIONS 02-03-2011
18. 20110028516 STABILIZED AND PRESERVED KETOIFEN OPHTHALMIC COMPOSITIONS 02-03-2011
19. 20110028422 COMBINATION OF NILOTINIB AND A NITROGEN MUSTARD ANALOGUE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA 02-03-2011
20. 20110027284 NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF 02-03-2011
21. 20110021536 Crystalline Forms and Two Solvated Forms of 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quino- lin-2(1H)-one Lactic Acid Salts 01-27-2011
22. 20110021502 USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION 01-27-2011
23. 20110020368 TREATING CANCER BY DOWN-REGULATING FRIZZLED-4 AND/OR FRIZZLED-1 01-27-2011
24. 20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes 01-27-2011
25. 20110015425 PROCESS - improved processes for the production of 2-amino-2-[2-ethyl]propane-1,3-diols, and to compounds for use therein 01-20-2011
26. 20110009383 METHOD OF TREATING MIXED LINEAGE LEUKEMIA GENE-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIAS 01-13-2011
27. 20110009340 COMBINATION OF AN IRON CHELATOR AND AN IMMUNOSUPPRESSANT AND USE THEREOF 01-13-2011
28. 20110008334 NOGO-A BINDING WITH ENHANCED AFFINITY AND PHARMACEUTICAL USE THEREOF 01-13-2011
29. 20110005518 METHODS AND UNIT DOSE FORMULATIONS FOR THE INHALATION ADMINISTRATION OF AMINOGLYCOSIDE ANTIBIOTICS 01-13-2011
30. 20110003002 SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND THREE LINEAR POLYLACTIDE-CO-GLYCOLIDE POLYMERS 01-06-2011
31. 20100331387 LYOPHILIZED PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions that include a poorly water-soluble therapeutic compound an aqueous solvent 12-30-2010
32. 20100331264 PRESERVING SECONDARY PEPTIDE STRUCTURE - method of preserving the 12-30-2010
33. 20100326877 PACKAGING POUCH - pouch for containing a product 12-30-2010
34. 20100323952 Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections 12-23-2010
35. 20100317627 Treatment of HCV Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C 12-16-2010
36. 20100316713 PHARMACEUTICAL COMPOSITION - The application relates to solid pharmaceutical compositions suitable for oral administration comprising an 12-16-2010
37. 20100311805 COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION 12-09-2010
38. 20100307839 COUNTING SCALE AND METHOD OF COUNTING - counting scale can total the number of common articles transferred relative to the counting scale, when the 12-09-2010
39. 20100305150 TUBEROUS SCLEROSIS TREATMENT - Rapamycin derivatives for use in the treatment of neurocutaneous disorders 12-02-2010
40. 20100304017 URETHANE AND OLIGOURETHANE DERIVATIVES AND CORRESPONDING USES AND METHODS FOR PRODUCING WATER MARKS USING THE OFFSET PRINTING TECHNIQUE 12-02-2010
41. 20100303919 PHARMACEUTICAL COMPOSITIONS COMPRISING FLUVASTATIN 12-02-2010
42. 20100303906 SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME 12-02-2010
43. 20100298353 Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment 11-25-2010
44. 20100298338 METHOD OF OPTIMIZING THE TREATMENT OF PROLIFERATIVE DISEASES MEDIATED BY THE TYROSINE KINASE RECEPTOR KIT 11-25-2010
45. 20100292291 FORMULATIONS OF DEACETYLASE INHIBITORS - stable parenteral formulation of histone deacetylase inhibitors 11-18-2010
46. 20100291217 PHARMACEUTICAL COMPOSITIONS - for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient 11-18-2010
47. 20100291216 PHARMACEUTICAL COMPOSITIONS - for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient 11-18-2010
48. 20100287884 POWDER CONDITIONING OF UNIT DOSE DRUG PACKAGES 11-18-2010
49. 20100286409 SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PH- ENYL]-2E-2-PROPENAMIDE 11-11-2010
50. 20100286031 Antibiotic Formulations, Unit Doses, Kits and Methods 11-11-2010
51. 20100282247 TREATMENT OF PULMONARY DISORDERS WITH AEROSOLIZED MEDICAMENTS SUCH AS VANCOMYCIN 11-11-2010
52. 20100280257 PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS 11-04-2010
53. 20100280035 SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER 11-04-2010
54. 20100280003 COMBINATIONS OF JAK INHIBITORS - pharmaceutical combination comprising 11-04-2010
55. 20100278881 USE OF CALCITONIN IN OSTEOARTHRITIS - novel use of calcitonin in osteoarthritis and to methods of treating and/or preventing osteoarthritis in mammals 11-04-2010
56. 20100278824 COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER 11-04-2010
57. 20100273719 USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA 10-28-2010
58. 20100272823 PULMONARY DELIVERY PARTICLES COMPRISING WATER INSOLUBLE OR CRYSTALLINE ACTIVE AGENTS 10-28-2010
59. 20100272809 MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES 10-28-2010
60. 20100272717 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER 10-28-2010
61. 20100267965 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors 10-21-2010
62. 20100267789 TABLET FORMULATIONS COMPRISING VALSARTAN 10-21-2010
63. 20100267787 Pharmaceutical Compositions - Provided are compositions comprising aqueous solutions of valsartan suitable for oral administration 10-21-2010
64. 20100267786 DUAL ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NE UTRAL ENDOPEPTIDASE (EP) INHIBITOR 10-21-2010
65. 20100267682 CORTICOSTEROIDS TO TREAT EPOTHILONE OR EPOTHILONE DERIVATIVE INDUCED DIARRHEA 10-21-2010
66. 20100267675 Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators 10-21-2010
67. 20100266704 OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS 10-21-2010
68. 20100266696 Organic Compounds - process of preparing a particulate and substantially crystalline drug substance 10-21-2010
69. 20100266608 IL-17 Antagonistic Antibodies - IL-17 binding molecule in particular an antibody to human IL-17 more preferably a human antibody to human IL-17 is 10-21-2010
70. 20100261726 TREATMENT OF AML - method of treating a warm-blooded animal having acute myeloid leukemia which is resistant to conventional chemotherapy 10-14-2010
71. 20100256080 ORGANIC COMPOUNDS - compound The instant invention relates to a compound of formulae 10-07-2010
72. 20100255485 BIOMARKERS FOR THE ONSET OF NEURODEGENERATIVE DISEASES 10-07-2010
73. 20100254976 USE OF PROTEASE NEXIN 1 INHIBITORS TO REDUCE METASTASIS 10-07-2010
74. 20100249429 PROCESS FOR THE MANUFACTURE OF VALSARTAN 09-30-2010
75. 20100249204 CALCIUM SALTS OF INDOLE DERIVED STATINS - of the formula STR00001 wherein R 09-30-2010
76. 20100249136 ORGANIC COMPOUNDS - The invention concerns the use an mGluR modulator, e 09-30-2010
77. 20100247658 ORGANIC COMPOUNDS - process for reducing the tendency of a drug substance to aggregate and/or agglomerate during storage 09-30-2010
78. 20100247645 PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN 09-30-2010
79. 20100247608 PHARMACEUTICAL COMPOSITIONS COMPRISING HGH FOR ORAL DELIVERY 09-30-2010
80. 20100244349 Clamp - device is provided for use to securely clamp a medical mechanism to a person carrier such as a lifter 09-30-2010
81. 20100240744 METHODS FOR THE TREATMENT OF DEMENTIA BASED ON APO E GENOTYPE 09-23-2010
82. 20100240680 Purine derivatives as a2a agonists - Compounds of formula : or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R 09-23-2010
83. 20100239524 MICROPARTICLES PREPARED USING AN IONIC LIQUID 09-23-2010
84. 20100234467 METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR 09-16-2010
85. 20100234408 PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF NEUROFIBROMATOSIS 09-16-2010
86. 20100233716 TRANSPLANT REJECTION MARKERS - analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection 09-16-2010
87. 20100233253 EXTENDED RELEASE GASTRO-RETENTIVE ORAL DRUG DELIVERY SYSTEM FOR VALSARTAN 09-16-2010
88. 20100222362 N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES 09-02-2010
89. 20100222360 Treatment of Malignant Peripheral Nerve Sheath Tumors 09-02-2010
90. 20100222334 Pharmaceutical Formulation of Valsartan - pharmaceutical composition in a form of suspension for oral administration comprising valsartan or its 09-02-2010
91. 20100216828 METHODS AND COMPOSITIONS FOR TREATING CANCERS 08-26-2010
92. 20100216254 DRUG MONITORING ASSAY - method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher 08-26-2010
93. 20100215734 PHARMACEUTICAL COMPOSITIONS - pharmaceutical composition in solid form comprising a poorly water soluble drug 08-26-2010
94. 20100215666 IL-17 ANTAGONISTIC ANTIBODIES - IL-17 binding molecule in particular an antibody to human IL-17 more preferably a human antibody to human IL-17 is 08-26-2010
95. 20100210717 PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLIC ACID OR MYCOPHENOLATE SALT 08-19-2010
96. 20100210673 PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR SYSTEMIC MASTOCYTOSIS 08-19-2010
97. 20100210650 ISOXAZOLE COMPOUND FOR THE TREATMENT OF CANCER 08-19-2010
98. 20100210526 ORAL ADMINISTRATION OF A CALCITONIN - The invention is directed to a method of administering pharmaceutical compositions comprising peptide drugs such 08-19-2010
99. 20100209480 GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS 08-19-2010
100. 20100204190 NEW COMBINATIONS - combination of organic compounds a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and 08-12-2010
101. 20100203133 HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula STR00001 or a 08-12-2010
102. 20100197804 PHARMACEUTICAL COMPOSITIONS COMPRISING TERBINAFINE 08-05-2010
103. 20100197629 ORAL PHARMACEUTICAL SOLUTIONS CONTAINING TELBIVUDINE 08-05-2010
104. 20100196957 CLONING AND CHARACTERIZATION OF 5' FLANKING REGIONS OF A HUMAN AGGRECANASE-1 GENE 08-05-2010
105. 20100196467 THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT 08-05-2010
106. 20100196365 USE OF IMIDAZOQUINOLINES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS 08-05-2010
107. 20100190800 COMBINATON OF PYRIMIDYLAMINOBENZAMIDE COMPOUNDS AND IMATINIB FOR TREATING OR PREVENTING PROLIFERATIVE DISEASES 07-29-2010
108. 20100184998 ORGANIC COMPOUNDS - olefin metathesis processes for the manufacture of a compound of the formula STR00001 which is a novel useful intermediate in the 07-22-2010
109. 20100184991 PREPARATION OF TERAZOLE DERIVATIVES - process for the preparation of -pyrrolidine-1H-tetrazole derivatives of formula STR00001 whereinR 07-22-2010
110. 20100184820 COMBINATIONS COMPRISING STAUROSPORINES - method of treating myelodysplastic syndromes lymphomas and leukemias 07-22-2010
111. 20100184798 Methods to Predict Cholesterol Elevations during Immunosuppressant Therapy 07-22-2010
112. 20100184779 METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS 07-22-2010
113. 20100184743 USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION 07-22-2010
114. 20100179208 Use of HDAC Inhibitors for the Treatment of Bone Destruction 07-15-2010
115. 20100179182 PHARMACEUTICAL FORMULATION - processes for making and forms of solid dispersions of pharmaceutical active ingredients 07-15-2010
116. 20100179179 INHIBITORS OF THE MUTANT FORM OF KIT - the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is 07-15-2010
117. 20100179175 USE OF PKC INHIBITORS IN OCULAR DISEASES 07-15-2010
118. 20100178344 Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles 07-15-2010
119. 20100178336 STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE 07-15-2010
120. 20100173934 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER 07-08-2010
121. 20100172869 METHOD FOR TREATING MULTIPLE SCLEROSIS - Methods for treating multiple sclerosis and clinically isolated syndromes suggestive of MS are provided 07-08-2010
122. 20100168229 Process for the preparation of optically active compounds using transfer hydrogenation 07-01-2010
123. 20100168153 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]q- uinolin-1-yl)-phenyl]-propionitrile 07-01-2010
124. 20100168132 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS 07-01-2010
125. 20100168078 S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS 07-01-2010
126. 20100168060 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF 07-01-2010
127. 20100167302 METHOD FOR PREDICTING THE RESPONSE OF A SUBJECT SUFFERING FROM A VIRAL INFECTION OF THE LIVER TO AN ANTIVIRAL THERAPY 07-01-2010
128. 20100166865 NANOPARTICLE COMPOSITIONS - method of Nanoparticle-based therapy for a mammalian subject is disclosed 07-01-2010
129. 20100166758 NOVEL ANTIBODY MOLECULES AND NUCLEIC ACIDS 07-01-2010
130. 20100166750 Indications for Anti-IL-1 Beta Therapy - This invention relates to a novel use of IL-1 07-01-2010
131. 20100166671 ORGANIC COMPOUNDS - Medicaments comprising an antimuscarinic agent a beta-2 adrenoreceptor agonist and a corticosteroid for the treatment of 07-01-2010
132. 20100163021 SYSTEM FOR DELIVERING NEBULIZED CYCLOSPORINE AND METHODS OF TREATMENT 07-01-2010
133. 20100160437 TOPICAL COMPOSITION COMPRISING A CYCLOFRUCTAN, A CARRIER AND A DRUG 06-24-2010
134. 20100160393 CRYSTAL FORM OF EPOTHILONE B AND USE IN PHARMACEUTICAL COMPOSITIONS 06-24-2010
135. 20100160381 RAF Inhibitors for the Treatment of Thyroid Cancer 06-24-2010
136. 20100160259 DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST 06-24-2010
137. 20100160257 USE OF HDAC INHIBITORS FOR THE TREATMENT OF MYELOMA 06-24-2010
138. 20100154093 SAFETY HELMET ATTACHMENT AND METHOD FOR SHIELDING EYES 06-24-2010
139. 20100152458 COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES 06-17-2010
140. 20100152299 Process for making compositions with poorly compressible therapeutic compounds 06-17-2010
141. 20100152101 TRIAZOL COMPOUNDS FOR TREATING BIOFILM FORMATION 06-17-2010
142. 20100151033 OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS 06-17-2010
143. 20100144811 COMBINATION - , especially a pharmaceutical composition, comprising as active ingredients an AT 06-10-2010
144. 20100144750 Use of N-Phenyl-2-Pyrimidineamine Derivatives Against Mast Cell-Based Diseases Like Allergic Disorders 06-10-2010
145. 20100143956 PREDICTIVE RENAL SAFETY BIOMARKERS AND BIOMARKER SIGNATURES TO MONITOR KIDNEY FUNCTION 06-10-2010
146. 20100143493 OPHTHALMIC SOLUTIONS - ophthalmic solution comprising a hydrogen peroxide source in an amount sufficient to result in between about 06-10-2010
147. 20100137398 USE OF HDAC INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL CANCERS 06-03-2010
148. 20100130749 METHODS - The invention related to a novel process novel process steps and novel intermediates useful in the synthesis of pharmaceutically active 05-27-2010
149. 20100130616 SALT OF ALISKIREN WITH OROTIC ACID - new salt of aliskiren the respective production and usage and pharmaceutical preparations containing such a salt 05-27-2010
150. 20100130408 USE OF MODIFIED CYCLOSPORINS - Disclosed are non-immunosuppressive cyclophilin-binding cyclosporine having useful properties in the prevention or 05-27-2010
151. 20100126502 SELF-SEALING T-PIECE AND VALVED T-PIECE - Apparatus and components for coupling fluid or gas conducting elements such as apparatus and components for 05-27-2010
152. 20100120921 RENIN INHIBITORS FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH HIGH SODIUM DIET 05-13-2010
153. 20100120877 ADDITIONAL THERAPEUTIC USE - use of an AT 05-13-2010
154. 20100120773 METHOD OF TREATING DISORDERS MEDIATED BY THE FIBROBLAST GROWTH FACTOR RECEPTOR 05-13-2010
155. 20100120746 USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN 05-13-2010
156. 20100119540 Vaccination Regimen for B-Cell Vaccines - This invention relates to the field of vaccination and treatment or prevention diseases 05-13-2010
157. 20100113801 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid 05-06-2010
158. 20100113607 Pharmaceutical Compositions - method for the topical treatment of nail diseases, e 05-06-2010
159. 20100113501 Ophthalmic Composition Comprising Ascomycin 05-06-2010
160. 20100108058 POWDER DISPERSION APPARATUS, METHOD OF MAKING AND USING THE APPARATUS, AND COMPONENTS THAT CAN BE USED ON THE APPARATUS AND OTHER DEVICES 05-06-2010
161. 20100105696 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS 04-29-2010
162. 20100098662 TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS 04-22-2010
163. 20100093749 COMPOUNDS - The invention provides acid addition salts of 3--4-[2--quinazolin-4-yl]-pyrro- le-2 5-dione crystalline forms thereof 04-15-2010
164. 20100093739 METHOD FOR DECREASING CAPILLARY PERMEABILITY IN THE RETINA 04-15-2010
165. 20100093732 Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms 04-15-2010
166. 20100093672 USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived 04-15-2010
167. 20100093603 USE OF ORGANIC COMPOUNDS - use of a renin inhibitor or a pharmaceutically acceptable salt thereof 04-15-2010
168. 20100087545 PURIFICATION PROCESS - Process for the preparation of pure allylamine pharmaceutical terbinafine of formula I STR00001 in free base form or acid 04-08-2010
169. 20100087463 PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT 04-08-2010
170. 20100087432 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY 04-08-2010
171. 20100086518 TREATMENT OF MELANOMA - Methods of treating melanoma include administering a compound of Structure I a tautomer of the compound 04-08-2010
172. 20100076084 Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes 03-25-2010
173. 20100076067 BIODEGRADABLE BLOCK COPOLYMERIC COMPOSITIONS FOR DRUG DELIVERY 03-25-2010
174. 20100075997 USE OF PKC INHIBITORS IN TRANSPLANTATION 03-25-2010
175. 20100073919 ACCESSORY AND METHOD FOR A MAILBOX - accessory that can be mounted over a mailbox has a base with a pair of sidewalls that are spaced to straddle the 03-25-2010
176. 20100069458 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER 03-18-2010
177. 20100069318 COMBINATION OF AN HDAC INHIBITOR AND AN ANTIMETABOLITE 03-18-2010
178. 20100069296 USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE 03-18-2010
179. 20100068298 NUTRITIONAL SUPPLEMENT COMPOSITION FOR TREATMENT OF OCULAR DISEASES 03-18-2010
180. 20100068288 MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES 03-18-2010
181. 20100068265 GELATIN CAPSULES COMPRISING AN ACID - pharmaceutical composition in the form of a gelatin capsule comprising a pharmaceutically acceptable acid 03-18-2010
182. 20100063029 USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS 03-11-2010
183. 20100056590 POLYMORPHIC FORMS OF DEFERASIROX (ICL670A) 03-04-2010
184. 20100056558 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS 03-04-2010
185. 20100056481 CRYSTALLINE FORMS OF ZOLEDRONIC ACID - new crystalline forms of low water soluble salts of zoledronic acid the process for preparation of these 03-04-2010
186. 20100056476 PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN 03-04-2010
187. 20100056467 COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS 03-04-2010
188. 20100056460 COMBINATION OF ORGANIC COMPOUNDS - combination such as a combined preparation or a pharmaceutical composition 03-04-2010
189. 20100056426 USE OF IRON CHELATOR FOR THE TREATMENT OF MYOCARDIAL INFARCTION 03-04-2010
190. 20100055709 Tubulin Mutation Diagnostic - methods for determining the potential of a subject to respond to a particular therapeutic agent 03-04-2010
191. 20100055049 INSULIN DERIVATIVE FORMULATIONS FOR PULMONARY DELIVERY 03-04-2010
192. 20100048716 CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE 02-25-2010
193. 20100048654 USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION 02-25-2010
194. 20100047306 PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES 02-25-2010
195. 20100041918 CYCLOPENTENE DIOL MONOACETATE DERIVATIVES 02-18-2010
196. 20100041887 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS 02-18-2010
197. 20100041884 CRYSTAL MODIFICATIONS-3-(1H-INDOL-3-YL)-4- [4-METHYL-PIPERAZIN-1-YL)-QUINAZOLIN-4-YL] -PYRROLE-2, 5-D IONE 02-18-2010
198. 20100041666 Use of N-Phenyl-2-pyrimidineamine Derivativea Against Mast Cell-based Diseases Like Allergic Disorders 02-18-2010
199. 20100041641 USES OF METABOTROPIC GLUTAMATE RECEPTORS 02-18-2010
200. 20100040678 ORGANIC COMPOUNDS - various pharmaceutical compositions comprising an S1P receptor modulator, e 02-18-2010
201. 20100040677 FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS 02-18-2010
202. 20100040598 KIT OF PARTS COMPRISING AN ACID LABILE AND AN ACID RESISTANT PHARMACEUTICALLY ACTIVE INGREDIENT 02-18-2010
203. 20100038816 METHOD OF MAKING SOLID DISPERSIONS OF HIGHLY CRYSTALLINE THERAPEUTIC COMPOUNDS 02-18-2010
204. 20100035949 MICROEMULSION DOSAGE FORMS OF VALSARTAN AND METHODS OF MAKING THE SAME 02-11-2010
205. 20100034910 Spray drying process control of drying kinetics 02-11-2010
206. 20100034890 COMBINATIONS OF FORMOTEROL AND FLUTICASONE PROPIONATE FOR ASTHMA 02-11-2010
207. 20100029775 RENIN INHIBITORS FOR THE PREVENTION AND TREATMENT OF HYPERTENSION IN OBESE PATIENTS 02-04-2010
208. 20100029705 BETA-2-ADRENORECEPTOR AGONISTS - Compounds of formula STR00001 in free or salt or solvate form, where Ar is a group of formula STR00002 Y is carbon or 02-04-2010
209. 20100029647 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES 02-04-2010
210. 20100029550 ORGANIC COMPOUNDS - pharmaceutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e 02-04-2010
211. 20100028459 NUTRITIONAL SUPPLEMENT COMPOSITION FOR TREATMENT OF OCULAR DISEASES 02-04-2010
212. 20100028338 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER 02-04-2010
213. 20100022627 PREDICTIVE BIOMARKERS FOR CHRONIC ALLOGRAFT NEPHROPATHY 01-28-2010
214. 20100022565 PHARMACEUTICAL COMPOSITIONS - Provided is a pharmaceutical composition comprising a calcilytic agent which when administered orally to a subject induces 01-28-2010
215. 20100021921 MUTATED ABL KINASE DOMAINS - isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl 01-28-2010
216. 20100021920 MUTATED ABL KINASE DOMAINS - isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl 01-28-2010
217. 20100021539 Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation 01-28-2010
218. 20100011714 PACKAGE FOR MEDICAMENT - package for a medicament the package comprising a sleeve and a slide the slide having a medicament region for containing 01-21-2010
219. 20100010039 POLYMORPHIC CRYSTAL FORM OF A INDAN-2-YLAMINO-HYDROXYETHYL-QUINOLINONE MALEATE DERIVATIVE AS BETA-ADRENOCEPTOR AGONIST 01-14-2010
220. 20100009392 USE OF MELANOMA INHIBITORY ACTIVITY (MIA) PROTEIN AS AN EARLY INDICATOR FOR THERAPEUTIC RESPONSE IN MELANOMA 01-14-2010
221. 20100004303 TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS 01-07-2010
222. 20100004205 PHARMACEUTICAL COMPOSITIONS - Synergistic combinations of a squalene epoxidase inhibitor and a leucyl-tRNA synthetase inhibitor are provided 01-07-2010
223. 20100003321 SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME 01-07-2010
224. 20100003318 PROCESS FOR MAKING MULTIPARTICULATES USING A ROLLER COMPACTOR 01-07-2010
225. 20100003212 POLYMERS WITH ANTIMICROBIAL ACTIVITY CONTAINING QUATERNARY AMMONIUM GROUPS 01-07-2010
226. 20090327175 PHARMACOKINETIC MODELING OF MYCOPHENOLIC ACID 12-31-2009
227. 20090326239 FERMENTATIVE PREPARATION PROCESS FOR AND CRYSTAL FORMS OF CYTOSTATICS 12-31-2009
228. 20090326066 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS 12-31-2009
229. 20090325967 ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS 12-31-2009
230. 20090325948 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE 12-31-2009
231. 20090325912 QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS 12-31-2009
232. 20090324542 SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS 12-31-2009
233. 20090318445 PDF INHIBITORS - novel compounds that are inhibitors of peptidyl deformylase 12-24-2009
234. 20090318390 COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 12-24-2009
235. 20090317827 Receptor In Dendritic Cells - the use of GPR91 as a target in dendritic cells 12-24-2009
236. 20090317489 Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof 12-24-2009
237. 20090314639 MEANS AND DEVICES FOR ELECTRO-FILTRATION OF MOLECULES 12-24-2009
238. 20090312441 ORGANIC COMPOUNDS - solid pharmaceutical composition comprising a poorly water soluble drug a polymer which is solid at room temperature 12-17-2009
239. 20090312311 COMBINATION OF ORGANIC COMPOUNDS - a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of 12-17-2009
240. 20090312304 ORGANIC COMPOUNDS - 3 4-substituted piperidine compounds these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal 12-17-2009
241. 20090312290 COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND IMATINIB FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA 12-17-2009
242. 20090311216 RECOMBINANT INTERFERON-BETA WITH ENHANCED BIOLOGICAL ACTIVITY 12-17-2009
243. 20090308384 Apparatus and methods for delivery of medicament to a respiratory system 12-17-2009
244. 20090306405 PROCESS FOR MAKING N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E- -2-PROPENAMIDE AND STARTING MATERIALS THEREFOR 12-10-2009
245. 20090306160 METHODS FOR IMPROVING DRUG DISPOSITION - method for improving the bioavailability, preferably, oral bioavailability and/or drug disposition, e 12-10-2009
246. 20090306138 PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS 12-10-2009
247. 20090305995 AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR 12-10-2009
248. 20090304705 BIOMARKERS FOR CHRONIC TRANSPLANT DYSFUNCTION 12-10-2009
249. 20090299065 PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS 12-03-2009
250. 20090299064 METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB 12-03-2009
251. 20090298791 COMBINATIONS COMPRISING EPOTHILONES AND ANTIMETABOLITES 12-03-2009
252. 20090298743 HYDROPHOBIC COMPOSITIONS CONTAINING RECONSTITUTION ENHANCER 12-03-2009
253. 20090297494 Diagnostic and treatment of a mental disorder 12-03-2009
254. 20090292013 In-Situ Forming Implant for Animals - composition comprising a thermoplastic polymer a rate modifying agent and a biologically active agent 11-26-2009
255. 20090291960 PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS 11-26-2009
256. 20090286821 INHIBITORS OF TYROSINE KINASES - compounds of formula STR00001 wherein the substituents R1 R2 and R4 have the meaning as set forth and explained in the 11-19-2009
257. 20090286803 COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR 11-19-2009
258. 20090286795 USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER 11-19-2009
259. 20090286770 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma 11-19-2009
260. 20090285622 APPLICATOR UNIT - for use in applying a substance to a surface the applicator unit comprising: a body unit to which a container is movably disposed 11-19-2009
261. 20090281159 USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS 11-12-2009
262. 20090281113 METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS 11-12-2009
263. 20090281090 BIOMARKERS FOR THE PREDICTION OF RESPONSIVENESS TO CLOZAPINE TREATMENT 11-12-2009
264. 20090281069 ORGANIC COMPOUNDS - compounds of the formula, STR00001 and their use in therapy 11-12-2009
265. 20090280172 GALENIC FORMULATIONS OF ORGANIC COMPOUNDS 11-12-2009
266. 20090280131 IL-17 Antagonistic Antibodies - IL-17 binding molecule in particular an antibody to human IL-17 more preferably a human antibody to human IL-17 is 11-12-2009
267. 20090275758 PROCESS FOR PHENYLACETIC ACID DERIVATIVES 11-05-2009
268. 20090275553 DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST 11-05-2009
269. 20090275551 Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins 11-05-2009
270. 20090270482 ANALYSIS OF METHYLATED NUCLEIC ACID - method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue 10-29-2009
271. 20090270441 MACROLIDES - stabilization of poly-ene macrolides and to a particular macrolide obtained in crystalline form 10-29-2009
272. 20090269334 BIOMARKERS FOR GRAFT REJECTION - Methods are disclosed for diagnosing rejection in a transplanted subject monitoring rejection in a transplanted subject 10-29-2009
273. 20090264461 Polymorph of (R)-3- (2-Hydroxy-2, 2-Diphenyl -Acetoxy) -1- (Isoxazol-s-ylcarbamoyl-methyl)-1-Azoni A-Bicyclo-[2.2.2] Octane Bromide 10-22-2009
274. 20090264459 Organic Compounds - Compounds of formula in free or a pharmaceutically acceptable salt form, wherein X 10-22-2009
275. 20090264367 5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS 10-22-2009
276. 20090263355 DEAMIDATED INTERFERON-BETA 10-22-2009
277. 20090260623 Aeorosolization apparatus with air inlet shield 10-22-2009
278. 20090258929 Compositions and Methods for Modulating mTOR Signaling 10-15-2009
279. 20090258127 Container Rack of a Food Warmer and Method of Use 10-15-2009
280. 20090253811 MANUFACTURE PROCESS OF ORGANIC COMPOUNDS 10-08-2009
281. 20090253752 COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN 10-08-2009
282. 20090252793 PHARMACEUTICAL COMPOSITIONS - Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect 10-08-2009
283. 20090249898 Systems and methods for non-destructive mass sensing 10-08-2009
284. 20090247638 PHARMACEUTICAL USE OF COX-2-INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS 10-01-2009
285. 20090247607 dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION 10-01-2009
286. 20090247582 METHODS OF TREATING ATHEROSCLEROSIS - method for the prevention delay the onset and treatment of atherosclerosis which method comprises administering to 10-01-2009
287. 20090247581 Organic Compounds - process for the synthesis of -2'[2-1- ethyl] cinnamanilide or salts or pharmaceutically acceptable prodrugs thereof: STR00001 10-01-2009
288. 20090247548 PYRROLOPYRIMIDINE DERIVATIVES FOR TREATING PROLIFERATIVE DISEASES 10-01-2009
289. 20090247517 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY 10-01-2009
290. 20090246172 COMPOSITIONS COMPRISING EPOTHILONES AND THEIR USE FOR THE TREATMENT OF CARCINOID SYNDROME 10-01-2009
291. 20090239879 N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES 09-24-2009
292. 20090239878 COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF C-ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER ANTINEOPLASTIC AGENTS 09-24-2009
293. 20090239872 TREATMENT OF MESOTHELIOMA - method of treating a warm-blooded animal especially a human 09-24-2009
294. 20090238797 NICOTINE-CARRIER VACCINE FORMULATION - The present invention is in the fields of medicine, public health, vaccine and drug formulation 09-24-2009
295. 20090238468 2-D encoded symbol quality assessment - 2-D symbol orientation guide with parallel and spaced right angle guidelines with chevron-like spaces provided 09-24-2009
296. 20090234010 MANUFACTURE PROCESS OF ORGANIC COMPOUNDS 09-17-2009
297. 20090232803 ANTIBODIES TO HUMAN IL-1BETA 09-17-2009
298. 20090221761 PROCESS FOR REMOVING RESIDUAL VOLATILE MONOMERS FROM A POLYMER IN POWDER FORM 09-03-2009
299. 20090221665 Organic Compounds - combination of a 5-HT4 receptor agonist and a cholinesterase inhibitor and pharmaceutical compositions and formulations containing 09-03-2009
300. 20090221605 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS 09-03-2009
301. 20090221598 Use of Sanglifehrin in HCV - The present invention discloses the use of a cyclophilin-binding compound such as a sanglifehrin for the treatment and 09-03-2009
302. 20090221550 COMPOSITIONS FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS 09-03-2009
303. 20090221519 COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND 09-03-2009
304. 20090221503 USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS 09-03-2009
305. 20090218714 APPARATUS - for filling a cavity during production of a pharmaceutical dosage form 09-03-2009
306. 20090216047 Purification process - for the preparation of the allylamine pharmaceutical terbinafine of formula I STR00001 in free base form or acid addition salt 08-27-2009
307. 20090215816 Imidazo(1,2-a)Pyridine Derivatives Useful as Peptide Deformylase (PDF) Inhibitors 08-27-2009
308. 20090215813 HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS 08-27-2009
309. 20090215695 REGULATION OF CYTOKINE SYNTHESIS AND RELEASE 08-27-2009
310. 20090215679 Disease-associated proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder 08-27-2009
311. 20090215044 Receptor in Dendritic Cells - GPBAR1 for use as a target for selective inhibition of Th1 mediated immune responses 08-27-2009
312. 20090214645 PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT DRUG, A PH MODIFIER AND A RETARDING AGENT 08-27-2009
313. 20090214506 Use of TFPI to Treat Severe Bacterial Infections 08-27-2009
314. 20090209648 Phenylacetic Acid Derivatives - Compounds of formula pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof 08-20-2009
315. 20090209639 PROCESS FOR MODIFYING DRUG CRYSTAL FORMATION 08-20-2009
316. 20090209539 Pyrimidine derivatives as alk-5 Inhibitors 08-20-2009
317. 20090209495 USE OF EDG RECEPTOR BINDING AGENTS IN CANCER 08-20-2009
318. 20090209493 COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR 08-20-2009
319. 20090208997 GPR18 as a Biomaker for TH1 Mediated Immune Response 08-20-2009
320. 20090203798 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol 08-13-2009
321. 20090203679 GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS 08-13-2009
322. 20090203576 METHODS AND COMPOSITONS FOR PULMONARY DELIVERY OF INSULIN 08-13-2009
323. 20090202637 ORAL PHARMACEUTICAL COATED COMPOSITION FOR PULSATILE RELEASE 08-13-2009
324. 20090202565 TORC POLYNUCLEOTIDES AND POLYPEPTIDES AND METHOD OF USE 08-13-2009
325. 20090202541 COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL)-4-(3-P- YRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT 08-13-2009
326. 20090199938 Nitrocellulose Composition And Uses Therefor 08-13-2009
327. 20090199622 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY 08-13-2009
328. 20090197936 SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PH- ENYL]-2E-2-PROPENAMIDE 08-06-2009
329. 20090197815 COMBINATION OF SOMATOSTATIN-ANALOGS WITH DOPAMINE- OR GROWTH HORMONE RECEPTOR ANTAGONIST 08-06-2009
330. 20090196871 USE OF 4-PYRIDYLMETHYLPHTHALAZINES FOR CANCER TREATMENT 08-06-2009
331. 20090196029 DISCHARGE LAMP AND FIXTURE THEREFOR - lighting assembly includes a discharge lamp having a discharge tube with a longitudinal centerline reaching 08-06-2009
332. 20090192446 Pressure responsive fluid flow control valves 07-30-2009
333. 20090192211 CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION 07-30-2009
334. 20090192210 POLYMORPHS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E- -2-PROPENAMIDE 07-30-2009
335. 20090191606 ORGANIC COMPOUNDS - isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain 07-30-2009
336. 20090191264 EPOTHILONE COMPOSITIONS - This invention provides liposomal compositions comprising an epothilone 07-30-2009
337. 20090187029 PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E- -2-PROPENAMIDE 07-23-2009
338. 20090181023 Nogo-a binding with enhanced affinity and pharmaceutical use thereof 07-16-2009
339. 20090176857 Use of Organic Compounds - pharmaceutical composition use or method in the treatment of Irritable Bowel Syndrome characterized by mixed or alternating 07-09-2009
340. 20090176755 PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBIOTIC 07-09-2009
341. 20090176701 Anti-microbial agents that interact with the complement system 07-09-2009
342. 20090171639 Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase 07-02-2009
343. 20090170862 USE OF C-KIT INHIBITORS FOR THE TREATMENT OF MYELOMA 07-02-2009
344. 20090163551 Compositions and Methods for Treating Diseases 06-25-2009
345. 20090163523 Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor 06-25-2009
346. 20090162433 METHOD OF TREATMENT - The invention provides the use of darifenacin or a pharmaceutically acceptable derivative thereof 06-25-2009
347. 20090162132 APPLICATOR UNIT - for use in applying a substance to a surface the applicator unit comprising: a body unit to which a pressurizable container is in use 06-25-2009
348. 20090158636 DEVICE FOR CAPTURING SMALL PESTS - device can capture small pests with a sheet overlaying a perforated panel 06-25-2009
349. 20090156615 ORGANIC COMPOUNDS - heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase 06-18-2009
350. 20090156602 Organic Compounds - pharmaceutical combination comprising 06-18-2009
351. 20090156588 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES - 3 4-dihydro-benzo[e][1 3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or 06-18-2009
352. 20090156585 ORGANIC COMPOUNDS - specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of 06-18-2009
353. 20090156556 AMINOPROPANOL DERIVATIVES - Compounds of formula I: STR00001 wherein R 06-18-2009
354. 20090149543 SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LUMIRACOXIB 06-11-2009
355. 20090149469 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors 06-11-2009
356. 20090148522 HEATED ROLLER COMPACTION PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS 06-11-2009
357. 20090143597 Ionic Liquids Based on Imidazolium Salts Incorporating a Nitrile Functionality 06-04-2009
358. 20090143479 PHARMACEUTICAL COMPOSITIONS COMPRISING TERBINAFINE 06-04-2009
359. 20090143469 SALTS OF NATEGLINIDE - salts of organic acid in particular salt of nateglinide combined preparations comprising one or more salts of nateglinide and 06-04-2009
360. 20090143340 Pyrocatechin Derivatives - of formula I STR00001 wherein R illustrates a group of formulae Ia, Ib, Ic or Id STR00002 R 06-04-2009
361. 20090137805 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES - novel amides and a process for preparing these amides 05-28-2009
362. 20090137804 Compounds and Compositions as Protein Kinase Inhibitors 05-28-2009
363. 20090137566 Substituted Piperdines as Renin Inhibitors 05-28-2009
364. 20090137552 Organic Compound - new crystalline form II of N-benzoyl-staurosporine 05-28-2009
365. 20090137462 PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTATIN ANALOGUES 05-28-2009
366. 20090136970 NOGO RECEPTOR HOMOLOGUES AND THEIR USE - This invention relates to gene polypeptides and polynucleotides that encode proteins of the Nogo-66 receptor 05-28-2009
367. 20090136965 Use of antibody-ligand binding to characterise diseases 05-28-2009
368. 20090136484 Novel antibody molecules and nucleic acids 05-28-2009
369. 20090131528 SALT - new salt of aliskiren the respective production and usage and pharmaceutical preparations containing such a salt 05-21-2009
370. 20090131477 NEW USE OF ILOPERIDONE - use of iloperidone in the treatment of affective disorders, including bipolar mood disorders 05-21-2009
371. 20090131457 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders 05-21-2009
372. 20090131450 USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS 05-21-2009
373. 20090131437 DISUBSTITUTED UREAS AS KINASE INHIBITORS 05-21-2009
374. 20090131436 Pyrimidine Derivatives - Novel pyrimidine derivatives of formula to processes for their production their use as pharmaceuticals and to pharmaceutical 05-21-2009
375. 20090131408 Organic Compounds - novel aza-thia-benzoazulene derivatives of formula I as defined in the claims 05-21-2009
376. 20090131404 Combinations - combination especially a pharmaceutical composition comprising an insulin secretion enhancer or a pharmaceutically acceptable salt 05-21-2009
377. 20090123566 USE OF A PHOSPHATE ADSORBENT TO COMBAT VASCULAR DISEASES 05-14-2009
378. 20090123424 Methods of protein purification and recovery 05-14-2009
379. 20090118277 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors 05-07-2009
380. 20090118273 Compounds and Compositions as Protein Kinase Inhibitors 05-07-2009
381. 20090118160 HETEROCYCLIC COMPOUNDS AND METHODS OF USE 05-07-2009
382. 20090117181 Tablet comprising fluvastatin and carmellose calcium 05-07-2009
383. 20090111839 Process for Preparing Amorphous Rosuvastatin Calcium of Impurities 04-30-2009
384. 20090110734 QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS 04-30-2009
385. 20090107367 Portable power tool rest - platform of generally rectangular configuration and of a size to accommodate a portable power tool 04-30-2009
386. 20090105322 PHARMACEUTICAL COMPOSITION COMPRISING VALSARTAN 04-23-2009
387. 20090105285 PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR 04-23-2009
388. 20090104263 5-HT4 partial agonist pharmaceutical compositions 04-23-2009
389. 20090104149 Compositions For HCV Treatment - The present invention concerns a pharmaceutical combination comprising 04-23-2009
390. 20090099241 PHARMACEUTICAL COMPOSITION CONTAINING ANTIHYPERTENSIVE AGENTS 04-16-2009
391. 20090099103 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER 04-16-2009
392. 20090098137 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER 04-16-2009
393. 20090088479 SALT OF ALISKIREN WITH SULFURIC ACID - new salt of aliskiren the respective production and usage and pharmaceutical preparations containing such a salt 04-02-2009
394. 20090088373 USE OF COMPOSITIONS TO ENHANCE INNATE IMMUNE RESPONSE 04-02-2009
395. 20090081741 SINGLE COLONIES OF MYXOBACTERIA CELLS - single colony of myxobacterium cells, a process for its production and its use 03-26-2009
396. 20090081732 ANTIBODIES TO HUMAN IL-1BETA 03-26-2009
397. 20090076062 Organic Compounds 03-19-2009
398. 20090075972 Use of Midostaurin for Treating Gastrointestinal Stromal Tumors 03-19-2009
399. 20090069394 CANCER TREATMENT WITH EPOTHILONES - in vivo regimen for the treatment of a proliferative disease 03-12-2009
400. 20090069341 INHIBITORS OF HSP90 - use of benzoimidazolone compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of 03-12-2009
401. 20090069315 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders 03-12-2009
402. 20090069294 Organic Compounds - The present disclosure relates to XIAP inhibitor compounds of the formula I 03-12-2009
403. 20090069225 SOMATOSTATIN ANALOGUES - The invention provides cyclo[{4-Pro}-Phg-DTrp-Lys-Tyr 03-12-2009
404. 20090062395 RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION 03-05-2009
405. 20090062301 PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS 03-05-2009
406. 20090060899 COMPOSITION OF ORGANIC COMPOUNDS - novel uses of a construct consisting of virus-like particle structure chemically coupled to a fragment of the A 03-05-2009
407. 20090060848 PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL 03-05-2009
408. 20090059729 MULTIFUNCTION REMINDER SYSTEM - reminder system has a user interface with a microphone, display and at least one manually operable control 03-05-2009
409. 20090054653 ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE 02-26-2009
410. 20090054628 METHOD AND SYSTEM FOR IN VITRO PROTEIN FOLDING 02-26-2009
411. 20090054512 USE OF ORGANIC COMPOUNDS - method for improving glucose control by administering a DPP-IV inhibitor to a patient in need thereof, before or with the 02-26-2009
412. 20090054404 USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN 02-26-2009
413. 20090053195 BIOMARKERS FOR ACUTE GRAFT REJECTION - Methods are disclosed for the early non-invasive diagnosing of acute rejection in a transplanted subject 02-26-2009
414. 20090048344 Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid 02-19-2009
415. 20090048281 Organic Compounds - Compounds of Formula , in salt or zwitterionic form wherein R 02-19-2009
416. 20090048266 Effects of Inhibitors of Fgfr3 on Gene Transcription 02-19-2009
417. 20090048230 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS 02-19-2009
418. 20090048157 USE OF ORGANIC COMPOUNDS - This invention relates generally to calcitonin and their use in bone growth 02-19-2009
419. 20090043379 DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES 02-12-2009
420. 20090043256 Hyperthermia, system, method and components 02-12-2009
421. 20090041775 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract 02-12-2009
422. 20090041715 Epothilone Combinations - combinations of an epothilone with two or more other antineoplastic agents for simultaneous 02-12-2009
423. 20090041675 Organic compounds - medicament comprising, separately or together, a compound of formula I STR00001 in free or salt or solvate form, where W, R 02-12-2009
424. 20090036507 BIS (CYANOPHENYL) METHYL-TRIAZOLE FOR USE IN PREVENTION OF BREAST CANCER 02-05-2009
425. 20090036432 Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic 02-05-2009
426. 20090036423 IMMUNOSUPPRESANT COMPOUNDS AND COMPOSITIONS 02-05-2009
427. 20090036352 DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES COMPRISING RAPAMYCIN AND DERIVATIVES THEREOF 02-05-2009
428. 20090029910 COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES 01-29-2009
429. 20090023805 METHOD OF ADMINISTRATION - the use of mycophenolic acid a salt or prodrug thereof in immunosuppression 01-22-2009
430. 20090023768 RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA 01-22-2009
431. 20090023754 Modified release famciclovir pharmaceutical compositions 01-22-2009
432. 20090022730 METHODS AND COMPOSITIONS FOR ASSESSING ACUTE REJECTION 01-22-2009
433. 20090018325 PROCESS FOR PREPARING L-NUCLEIC ACID DERIVATIVES AND INTERMEDIATES THEREOF 01-15-2009
434. 20090018127 Ergoline Derivatives - Disclosed are ergoline derivatives, Formula , wherein either each of R 01-15-2009
435. 20090018109 COMBINATIONS OF STEROIDS AND METHYLXANTHINE COMPOUNDS 01-15-2009
436. 20090017015 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders 01-15-2009
437. 20090012298 Process for the Preparation of Rapamycin Derivatives 01-08-2009
438. 20090012105 Combination of Mtor Inhibitor and Antipolate Compound 01-08-2009
439. 20090012066 Method of Use of Deacetylase Inhibitors - methods of treating and/or preventing pathologic cardiac hypertrophy and heart failure comprising 01-08-2009
440. 20090005984 APPARATUS AND METHOD FOR TRANSIT PREDICTION 01-01-2009
441. 20090005419 Organic Compounds - assay for identifying an agent that modulates the interaction of a mRNA with a target protein, e 01-01-2009
442. 20090005361 Combination of Organic Compounds - combination such as a combined preparation or pharmaceutical composition 01-01-2009
443. 20090004283 Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide Polymers 01-01-2009
444. 20090003921 DISPENSER AND METHOD FOR DISPENSING FLUIDS 01-01-2009
445. 20080319222 Crystal forms of N- (trans-4-isopropylctyclohexylcarbonyl) -D-phenylalanine 12-25-2008
446. 20080319045 Combination of Histone Deacetylase Inhibitors and Radiation 12-25-2008
447. 20080319005 Phenylacetamides Suitable as Protein Kinase Inhibitors 12-25-2008
448. 20080318988 Pyrimidylaminobenzamide Derivatives For the Treatment of Neurofibromatosis 12-25-2008
449. 20080318940 Quinazolinone Derivatives as Vanilloid Antagonists 12-25-2008
450. 20080318838 PEPTIDES - PTH compounds having PTH-like activity and comprising at least one modification, said modification being either 1 12-25-2008
451. 20080317862 Organic Compounds Comprising a Glycopyrrolium Salt 12-25-2008
452. 20080317741 Biomarkers For Anti-Nogo-A Antibody Treatment in Spinal Cord Injury 12-25-2008
453. 20080312462 Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives 12-18-2008
454. 20080312456 PROCESS FOR THE SYNTHESIS OF PEPTIDES CONTAINING A 4-HYDROXY-PROLINE SUBSTRUCTURE 12-18-2008
455. 20080312322 Organic Compounds - compound of formula , in free or pharmaceutically acceptable salt form, where R 12-18-2008
456. 20080312316 Chromone Derivatives Useful as Antagonists of Vr1 Receptors 12-18-2008
457. 20080312313 Inhibitors of Ccr9 Activity - compound of formula , wherein the residues have various meanings, useful as pharmaceuticals 12-18-2008
458. 20080312302 Desferasirox Dispersible Tablets - The invention pertains to dispersible tablets comprising as active ingredient 4-[3 5-bis-[1 2 12-18-2008
459. 20080312256 Organic Compounds - compounds of the formula which are activators of glucokinase activity and 12-18-2008
460. 20080312252 Combination of Organic Compounds - pharmaceutical combination comprising 12-18-2008
461. 20080312250 Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide 12-18-2008
462. 20080312229 Organic Compounds - There are provided according to the invention compounds of formula in free or salt form, wherein R 12-18-2008
463. 20080312192 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases 12-18-2008
464. 20080311194 Dispersible Tablets Comprising Deferasirox 12-18-2008
465. 20080311188 SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL 12-18-2008
466. 20080306233 Process for Removing Residual Volatile Monomers from a Polymer in Powder form 12-11-2008
467. 20080306124 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands 12-11-2008
468. 20080306081 Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists 12-11-2008
469. 20080306064 Benzimidazole Derivatives - methods of preparing the same and their pharmaceutical uses for the treatment of inflammatory diseases including COPD 12-11-2008
470. 20080305494 Chemokine Ccl18 as a Biomarker 12-11-2008
471. 20080305172 OPHTHALMIC DEPOT FORMULATIONS FOR PERIOCULAR OR SUCONJUNCTIVAL ADMINISTRATION 12-11-2008
472. 20080300410 Organic Compounds - salts of aryl compounds as discussed below and to methods of manufacture thereof, as well as other subject matter 12-04-2008
473. 20080300293 COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND 12-04-2008
474. 20080300277 PROCESS TO IMPROVE STABILITY OF A PHARMACEUTICAL COMPOSITION 12-04-2008
475. 20080300245 Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors 12-04-2008
476. 20080300238 PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC 12-04-2008
477. 20080300237 Pharmaceutically Active Diazepanes - Leukocyte Function-Associated Antigen One is a cell adhesion molecule selectively expressed on leukocytes 12-04-2008
478. 20080300171 Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events 12-04-2008
479. 20080299190 Direct Compression Formulation and Process 12-04-2008
480. 20080299166 NOVEL BIOMATERIALS, THEIR PREPARATION AND USE 12-04-2008
481. 20080293939 QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS 11-27-2008
482. 20080293791 VALSARTAN SALTS - new salts of valsartan or crystalline also partly crystalline and amorphous salts of valsartan 11-27-2008
483. 20080293738 Formulation of Quinolinones - pharmaceutical formulation comprising: a compound of formula a tautomer of the compound 11-27-2008
484. 20080287553 PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN 11-20-2008
485. 20080287543 Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid 11-20-2008
486. 20080287501 THERAPEUTIC USES OF AN INSULIN SECRETION ENHANCER 11-20-2008
487. 20080287417 PHARMACEUTICAL COMPOSITIONS COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER 11-20-2008
488. 20080287416 Organic Compounds - There are provided according to the invention compounds of formula in free ors salt form, wherein R 11-20-2008
489. 20080287412 THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT 11-20-2008
490. 20080287389 Nucleoside analogs in combination therapy of herpes simplex infections 11-20-2008
491. 20080286363 Pharmaceutical Compositions for the Treatment of Inflammatory and Obstructive Airways Diseases 11-20-2008
492. 20080286356 Pharmaceutical compositions containing terbinafin and use thereof 11-20-2008
493. 20080286352 Liposome Compositions - method of liposome-based therapy for a mammalian subject is disclosed 11-20-2008
494. 20080286281 CD25 BINDING MOLECULES FOR THE USE IN THE TREATMENT OF MANIFESTATIONS OF REJECTION IN TRANSPLANTATION 11-20-2008
495. 20080286266 Novel Use of Il-1Beta Compounds - This invention relates to a novel use of IL-1 11-20-2008
496. 20080281136 CATALYST AND METHOD FOR CONVERTING NATURAL GAS TO HIGHER CARBON COMPOUNDS 11-13-2008
497. 20080280999 Process for Making Pharmaceutical Compositions with a Transient Plasticizer 11-13-2008
498. 20080280940 Rapamycin Derivative or an Impdh Inhibitor For Treating Polycystic Kidney Disease 11-13-2008
499. 20080280939 Combination of Organic Compounds - pharmaceutical combinations comprising an AT1 receptor blocker or pharmaceutically acceptable salts thereof and a 11-13-2008
500. 20080280880 Staurosporine Derivatives for Use in Alveolar Rhabdomyosarcoma 11-13-2008
501. 20080280871 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases 11-13-2008
502. 20080280817 MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION 11-13-2008
503. 20080279962 Method of Scintigraphy - combination comprising a pharmaceutically acceptable preparation of a compound of formula 11-13-2008
504. 20080279955 Pharmaceutical microparticles - Microparticles consisting of a matrix with a mixture of at least one hydrophobic biologically degradable polymer and 11-13-2008
505. 20080279948 Treatment of Asthma and Copd Using Triple-Combination Therapy 11-13-2008
506. 20080279932 Compounds - novel salt forms of vildagliptin , i 11-13-2008
507. 20080275114 Inhibitors of Ccr9 Activity - Compounds of formula , in which R 11-06-2008
508. 20080275035 Nitroimidazole Compounds - certain nitroimidazole compounds, which have interesting pharmaceutical properties 11-06-2008
509. 20080274189 Organic Compounds Comprising a Glycopyrr Onium Salt 11-06-2008
510. 20080273176 Display device and method - reflective or light redirecting device has a base with an overlaying pattern or light redirector 11-06-2008
511. 20080269490 Method for Asymmetric Hydrosilylation of Ketones 10-30-2008
512. 20080269343 GALENIC FORMULATIONS OF ORGANIC COMPOUNDS 10-30-2008
513. 20080269335 Crth2 Receptor Antagonists - There are provided according to the invention compounds of formula in free or salt form wherein R< 10-30-2008
514. 20080269312 Inhibitors of Ccr9 Activity - N--2,3-dihydro-1H-indols, wherein the indol is substituted by cyano, carboxy or alkylcarbonyloxy and their use as 10-30-2008
515. 20080269311 Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors 10-30-2008
516. 20080269269 Crystalline Forms of 4-Methyl-N- [3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3- (4-Pyridin-3-Yl-Pyrimidin-2-Ylamino) -Benzamide 10-30-2008
517. 20080268040 Organic Compounds Comprising a Glycopyrrolium Salt 10-30-2008
518. 20080267886 Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists 10-30-2008
519. 20080262254 Sphingolipids - The use of a metathesis catalyst in the preparation of a functionalized sphingolipid 10-23-2008
520. 20080262246 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors 10-23-2008
521. 20080262059 METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION 10-23-2008
522. 20080262050 Organic Compounds - Compounds of the formula are inhibitors of protein tyrosine phosphatases and thus may be employed for the treatment of conditions 10-23-2008
523. 20080262021 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors 10-23-2008
524. 20080262014 Use of Camptothecin Derivatives for the Treatment of Proliferative Diseases in a Fixed Dosing Regimen 10-23-2008
525. 20080261958 Combination of Organic Compounds - combination comprising: an angiotensin II receptor blocker or a pharmaceutically acceptable salt thereof 10-23-2008
526. 20080261864 Combination of nateglinide or repaglinide with at least one further antidiabetic compound 10-23-2008
527. 20080255369 Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction 10-16-2008
528. 20080255356 CHIRAL TERTIARY AMINOALKYLNAPHTHOLS - bipyrimidinyl diphosphine compounds of the formula wherein R is optionally substituted alkyl 10-16-2008
529. 20080255176 QUINOLINE DERIVATIVES - novel benzo[g]quinoline derivatives their preparation their use as pharmaceuticals and pharmaceutical compositions containing 10-16-2008
530. 20080255171 Combination of Nilotinib with Farnesyl Transferase Inhibitors 10-16-2008
531. 20080255149 Carboxyamine Compounds and Methods of Use Thereof 10-16-2008
532. 20080255139 Use Of 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-(Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide to Inhibit the Tyrosine Kinase Receptor C-Fms 10-16-2008
533. 20080255135 Novel 1-Aza-Bicycloalkyl Derivatives - compound of formula where X, R, Y, D, A and B are as defined herein 10-16-2008
534. 20080255084 Combination of Organic Compounds - combination such as a combined preparation or a pharmaceutical composition 10-16-2008
535. 20080255048 Pharmaceutical Composition - oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount 10-16-2008
536. 20080255029 Neuroendocrine Tumor Treatment - method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another 10-16-2008
537. 20080254116 Delta and Epsilon Crystal Forms of Imatinib Mesylate 10-16-2008
538. 20080254113 Microemulsion Formulations Comprising Particular Substance P Antagonists 10-16-2008
539. 20080254089 PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES 10-16-2008
540. 20080253988 Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases 10-16-2008
541. 20080249318 Process for phenylacetic acid derivatives 10-09-2008
542. 20080249104 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide 10-09-2008
543. 20080242686 PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN 10-02-2008
544. 20080242683 Organic Compounds - Compounds of or stereoisomers or pharmaceutically acceptable salts thereof, where W, R 10-02-2008
545. 20080242662 Organic Compounds - substituted 3 4- or higher substituted piperazine compounds the use thereof for the preparation of a pharmaceutical formulation for 10-02-2008
546. 20080242659 COMPOSITIONS AND METHODS FOR REDUCING CARDIOVASCULAR MORBIDITY AND/OR MORTALITY 10-02-2008
547. 20080238611 Authentication of source, plus, for goods and services system, method, and components 10-02-2008
548. 20080234490 Metal Salts of 2' - (1H-Tetrazol-5Yl) -1. 1'-Biphenyl-4-Carboxaldehyde 09-25-2008
549. 20080234294 Cxcr4 Binding Molecules - This invention relates to the use of a CXCR binding molecules as described in the specification, in WHIM syndrome 09-25-2008
550. 20080234285 Combination of Organic Compounds - combination such as a combined preparation or pharmaceutical composition 09-25-2008
551. 20080234179 ORALLY DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING A DELIVERY AGENT IN MICRONIZED FORM 09-25-2008
552. 20080233182 ORGANIC COMPOUNDS - method of protecting copper-sensitive compounds and/or compositions from decomposition 09-25-2008
553. 20080227980 Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative 09-18-2008
554. 20080227845 CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION 09-18-2008
555. 20080227825 Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV inhibitor preferably vildagliptin and metformin 09-18-2008
556. 20080227800 Pyrimidylaminobenzamide Derivatives for Hypereosinophilic Syndrome 09-18-2008
557. 20080227755 METHOD OF ADMINISTERING BISPHOSPHONATES - Bisphosphonates in particular more potent N-bisphosphonates such as zoledronic acid and derivatives 09-18-2008
558. 20080227125 Secreted Polypeptide Species Reduced in Cardiovascular Disorders 09-18-2008
559. 20080226737 Use of Calcitonin For the Treatment of Ra 09-18-2008
560. 20080226731 Pharmaceutical Compositions Comprising I Matinib and a Release Retardant 09-18-2008
561. 20080221336 Pparalpha/Gamma Agonists and Processes of Preparing 09-11-2008
562. 20080221200 Combination of Organic Compounds - combination such as a combined preparation or pharmaceutical composition 09-11-2008
563. 20080221126 Use of Hdac Inhibitors for the Treatment of Myeloma 09-11-2008
564. 20080221080 Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 09-11-2008
565. 20080221065 ORGANIC COMPOUNDS - Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition 09-11-2008
566. 20080219996 Molecular Markers Associated with Bone Metastasis 09-11-2008
567. 20080219977 Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer 09-11-2008
568. 20080216825 Insulated Cansister for Metered Dose Inhalers 09-11-2008
569. 20080214662 METHODS FOR THE TREATMENT OF DEMENTIA BASED ON APO E GENOTYPE 09-04-2008
570. 20080214596 BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES TO MTOR INHIBITORS 09-04-2008
571. 20080214595 Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders 09-04-2008
572. 20080214521 Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors 09-04-2008
573. 20080214445 Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib 09-04-2008
574. 20080213385 Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin 09-04-2008
575. 20080213330 Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons 09-04-2008
576. 20080207921 Organic Compounds - The invention related to a novel process novel process steps and novel intermediates useful in the synthesis of pharmaceutically 08-28-2008
577. 20080207739 Ophthalmic Uses of S1p Receptor Modulators 08-28-2008
578. 20080207692 Stabilized and preserved ketoifen ophthalmic compositions 08-28-2008
579. 20080207686 Peptide Deformylase (Pdf) Inhibitors 4 - compounds of formula 08-28-2008
580. 20080207648 Organic Compounds - Compounds of formula I in free or salt form, wherein R 08-28-2008
581. 20080207591 Organic Compounds - pharmaceutical combination comprising 08-28-2008
582. 20080207567 Treatment of Hcv Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C 08-28-2008
583. 20080207565 USE OF BISPHOSPHONATES FOR PAIN TREATMENT 08-28-2008
584. 20080207533 Pharmaceutical Compositions - pharmaceutical composition and granulates, prepared by a wet granulation process 08-28-2008
585. 20080207496 ORGANIC COMPOUND - combination which comprises a staurosporine derivative and an agent effective in preventing delaying or treating transplant rejection 08-28-2008
586. 20080206322 Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin 08-28-2008
587. 20080206240 Antilymphocyte Antibody Induction - immunosuppressive treatment combining a S1 P receptor modulator one or more immunosuppressive drug and an 08-28-2008
588. 20080206237 Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent 08-28-2008
589. 20080200692 Process For the Synthesis of Organic Compounds 08-21-2008
590. 20080200691 Process For the Synthesis of Organic Compounds 08-21-2008
591. 20080200687 Preparation of Terazole Derivatives - process for the preparation of -pyrrolidine-1H-tetrazole derivatives of formula wherein R 08-21-2008
592. 20080200510 Combination of Organic Compounds - combination such as a combined preparation or pharmaceutical composition 08-21-2008
593. 20080200489 Combination of Organic Compounds - pharmaceutical combination comprising 08-21-2008
594. 20080200488 Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag 08-21-2008
595. 20080200487 Salts of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide 08-21-2008
596. 20080200486 Combination Of Organic Compounds - pharmaceutical combination comprising 08-21-2008
597. 20080200483 Purine Derivatives for Use as Adenosin A-2A Receptor Agonists 08-21-2008
598. 20080200466 Organic Compounds For the Treatment of Inflammatory or Allergic Conditions 08-21-2008
599. 20080200438 Treatment of Autoimmune Diseases - Methods of treating various autoimmune diseases such as multiple sclerosis peripheral neuritis 08-21-2008
600. 20080199855 Identification And Characterization Of A Subset of Glioblastomas Sensitive To Treatment With Imatinib 08-21-2008
601. 20080199465 IMMUNOSUPPRESSIVE COMBINATION AND ITS USE IN THE TREATMENT OR PROPHYLAXIS OF INSULIN-PRODUCING CELL GRAFT REJECTION 08-21-2008
602. 20080199428 Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis 08-21-2008